{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:49:42Z","timestamp":1786981782035,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-022-02741-2","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T03:04:26Z","timestamp":1671678266000},"page":"273-281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Perioperative continuous infusions of factor VIII versus factor IX for patients with hemophilia A or B undergoing major surgery"],"prefix":"10.1007","volume":"55","author":[{"given":"Brandon","family":"Tse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosane","family":"Nisenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Floros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Jiwajee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Teitel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Sholzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"issue":"4","key":"2741_CR1","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/j.1365-2141.1992.tb06951.x","volume":"82","author":"U Martinowitz","year":"1992","unstructured":"Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D (1992) Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol 82(4):729\u2013734","journal-title":"Br J Haematol"},{"issue":"1","key":"2741_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1365-2516.2011.02552.x","volume":"18","author":"J Uprichard","year":"2012","unstructured":"Uprichard J, Adamidou D, Goddard NJ, Mann HA, Yee TT (2012) Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000\u20132010. Haemophilia 18(1):46\u201349","journal-title":"Haemophilia"},{"issue":"1","key":"2741_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1046\/j.1365-2516.1999.00210.x","volume":"5","author":"KB Thomas","year":"1999","unstructured":"Thomas KB, Urbancik W, Turecek PL, Gritsch H, Schreiber J, Weber A et al (1999) Continuous infusion of FVIII and FIX concentrates: in vitro analysis of clinically relevant parameters. Haemophilia 5(1):17\u201325","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"2741_CR4","first-page":"S15","volume":"7","author":"CR Hay","year":"1996","unstructured":"Hay CR, Doughty HI, Savidge GF (1996) Continuous infusion of factor VIII for surgery and major bleeding. Blood Coagul Fibrinolysis 7(Suppl 1):S15-19","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"2741_CR5","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1345\/aph.1A338","volume":"36","author":"JM Stachnik","year":"2002","unstructured":"Stachnik JM, Gabay MP (2002) Continuous infusion of coagulation factor products. Ann Pharmacother 36(5):882\u2013891","journal-title":"Ann Pharmacother"},{"issue":"3","key":"2741_CR6","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1111\/hae.14219","volume":"27","author":"I Pabinger","year":"2021","unstructured":"Pabinger I, Mamonov V, Windyga J, Engl W, Doralt J, Tangada S et al (2021) Results of a randomized phase III\/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgery. Haemophilia 27(3):e331\u2013e339","journal-title":"Haemophilia"},{"issue":"3","key":"2741_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1046\/j.1365-2141.2000.02226.x","volume":"110","author":"A Batorova","year":"2000","unstructured":"Batorova A, Martinowitz U (2000) Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. Br J Haematol 110(3):715\u2013720","journal-title":"Br J Haematol"},{"issue":"5","key":"2741_CR8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1046\/j.1365-2516.2002.00650.x","volume":"8","author":"D Dingli","year":"2002","unstructured":"Dingli D, Gastineau DA, Gilchrist GS, Nichols WL, Wilke JL (2002) Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates. Haemophilia 8(5):629\u2013634","journal-title":"Haemophilia"},{"issue":"9371","key":"2741_CR9","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","volume":"361","author":"PHB Bolton-Maggs","year":"2003","unstructured":"Bolton-Maggs PHB, Pasi KJ (2003) Haemophilias A and B. Lancet 361(9371):1801\u20131809","journal-title":"Lancet"},{"issue":"2","key":"2741_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000488060","volume":"45","author":"L Graf","year":"2018","unstructured":"Graf L (2018) Extended half-life factor VIII and factor IX preparations. Transfus Med Hemother 45(2):86\u201391","journal-title":"Transfus Med Hemother"},{"issue":"5","key":"2741_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00003088-199222050-00005","volume":"22","author":"S Bj\u00f6rkman","year":"1992","unstructured":"Bj\u00f6rkman S, Carlsson M, Berntorp E, Stenberg P (1992) Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies. Clin Pharmacokinet 22(5):385\u2013395","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2741_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1046\/j.1365-2516.2003.00762.x","volume":"9","author":"E Berntorp","year":"2003","unstructured":"Berntorp E, Bj\u00f6rkman S (2003) The pharmacokinetics of clotting factor therapy. Haemophilia 9(4):353\u2013359","journal-title":"Haemophilia"},{"issue":"8","key":"2741_CR13","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1046\/j.1365-2044.2001.02058-3.x","volume":"56","author":"AM Ho","year":"2001","unstructured":"Ho AM, Dion P, Karmakar MK, Cheng G, Derrick JL, Chung DC et al (2001) A pharmacokinetic model for factor VIII dosing during active haemorrhage in patients with haemophilia A. Anaesthesia 56(8):785\u2013790","journal-title":"Anaesthesia"},{"issue":"2","key":"2741_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1365-2141.1987.tb01303.x","volume":"66","author":"DM Stern","year":"1987","unstructured":"Stern DM, Knitter G, Kisiel W, Nawroth PP (1987) In vivo evidence of intravascular binding sites for coagulation factor IX. Br J Haematol 66(2):227\u2013232","journal-title":"Br J Haematol"},{"issue":"4","key":"2741_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/BF00194400","volume":"46","author":"S Bj\u00f6rkman","year":"1994","unstructured":"Bj\u00f6rkman S, Carlsson M, Berntorp E (1994) Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. Eur J Clin Pharmacol 46(4):325\u2013332","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"2741_CR16","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1111\/jth.12421","volume":"11","author":"D Feng","year":"2013","unstructured":"Feng D, Stafford KA, Broze GJ, Stafford DW (2013) Evidence of clinically significant extravascular stores of factor IX. J Thromb Haemost 11(12):2176\u20132178","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2741_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1182\/blood.V100.1.153","volume":"100","author":"T Gui","year":"2002","unstructured":"Gui T, Lin HF, Jin DY, Hoffman M, Straight DL, Roberts HR et al (2002) Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood 100(1):153\u2013158","journal-title":"Blood"},{"issue":"Suppl 1","key":"2741_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12959-016-0104-2","volume":"14","author":"DW Stafford","year":"2016","unstructured":"Stafford DW (2016) Extravascular FIX and coagulation. Thromb J 14(Suppl 1):35","journal-title":"Thromb J"},{"issue":"4","key":"2741_CR19","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1182\/blood-2009-01-195313","volume":"114","author":"G Tagariello","year":"2009","unstructured":"Tagariello G, Iorio A, Santagostino E, Morfini M, Bisson R, Innocenti M et al (2009) Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood 114(4):779\u2013784","journal-title":"Blood"},{"issue":"7","key":"2741_CR20","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/j.1538-7836.2008.03001.x","volume":"6","author":"S Schulman","year":"2008","unstructured":"Schulman S, Eelde A, Holmstr\u00f6m M, St\u00e5hlberg G, Odeberg J, Blomb\u00e4ck M (2008) Validation of a composite score for clinical severity of hemophilia. J Thromb Haemost 6(7):1113\u20131121","journal-title":"J Thromb Haemost"},{"issue":"Suppl 6","key":"2741_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW et al (2020) WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 26(Suppl 6):1\u2013158","journal-title":"Haemophilia"},{"issue":"5","key":"2741_CR22","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.16704","volume":"190","author":"R Rayment","year":"2020","unstructured":"Rayment R, Chalmers E, Forsyth K, Gooding R, Kelly AM, Shapiro S et al (2020) Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B. Br J Haematol 190(5):684\u2013695","journal-title":"Br J Haematol"},{"key":"2741_CR23","doi-asserted-by":"crossref","unstructured":"Park YS, Shin WJ, Kim KI (2017) Comparison of continuous infusion versus bolus injection of factor concentrates for blood management after total knee arthroplasty in patients with hemophilia. BMC Musculoskelet Disord [Internet]. [cited 2019 Apr 23];18. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5568057\/","DOI":"10.1186\/s12891-017-1720-0"},{"issue":"5","key":"2741_CR24","first-page":"474","volume":"14","author":"T Prelog","year":"2016","unstructured":"Prelog T, Dolni\u010dar MB, Kitanovski L (2016) Low-dose continuous infusion of factor VIII in patients with haemophilia A. Blood Transfus 14(5):474\u2013480","journal-title":"Blood Transfus"},{"issue":"3","key":"2741_CR25","doi-asserted-by":"publisher","first-page":"442","DOI":"10.4184\/asj.2018.12.3.442","volume":"12","author":"K Kobayashi","year":"2018","unstructured":"Kobayashi K, Imagama S, Ando K, Ito K, Tsushima M, Morozumi M et al (2018) Perioperative management of patients with hemophilia during spinal surgery. Asian Spine J 12(3):442\u2013445","journal-title":"Asian Spine J"},{"issue":"2","key":"2741_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/jocs.13530","volume":"33","author":"T Kanellopoulou","year":"2018","unstructured":"Kanellopoulou T, Nomikou E (2018) Replacement therapy for coronary artery bypass surgery in patients with hemophilia A and B. J Card Surg 33(2):76\u201382","journal-title":"J Card Surg"},{"issue":"3","key":"2741_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1365-2516.1996.tb00162.x","volume":"2","author":"NG Richardson","year":"1996","unstructured":"Richardson NG, Miller AL, O\u2019Shaughnessy DF (1996) Successful treatment of acute subdural haemorrhage with continuous intravenous infusion of factor VIII in a 17 year old with haemophilia A. Haemophilia 2(3):173\u2013176","journal-title":"Haemophilia"},{"issue":"1","key":"2741_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.5045\/br.2018.53.1.41","volume":"53","author":"KY Yoo","year":"2018","unstructured":"Yoo KY, Jung SY, Hwang SH, Lee SM, Park JH, Nam HJ (2018) Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX. Blood Res 53(1):41\u201348","journal-title":"Blood Res"},{"key":"2741_CR29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007458","author":"R Kruse-Jarres","year":"2022","unstructured":"Kruse-Jarres R, Peyvandi F, Oldenburg J, Chang T, Chebon S, Doral MY et al (2022) Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1\u20134 studies. Blood Adv. https:\/\/doi.org\/10.1182\/bloodadvances.2022007458","journal-title":"Blood Adv"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-022-02741-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-022-02741-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-022-02741-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T18:55:47Z","timestamp":1679856947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-022-02741-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["2741"],"URL":"https:\/\/doi.org\/10.1007\/s11239-022-02741-2","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"assertion":[{"value":"21 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MS has received unrestricted research funding from Takeda and Octapharma. She has previously received honoraria for advisory boards from Takeda, Octapharma, Bayer and NovoNordisk. JT has been a paid consultant and and Advisory Board member for Bayer, Takeda, Novo Nordisk, and Pfizer. He has received research support from Pfizer, Bayer, and Takeda. BT, RN, GF, and AJ have no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}